Feedback
Settings

Settings

Goto Application

30,747 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:G01N33/569

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 3,075
1.WO/2022/107737SARS-CoV-2 DETECTION KIT AND SARS-CoV-2 DETECTION METHOD
WO - 27.05.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No PCT/JP2021/041983 Applicant FUJIFILM CORPORATION Inventor UJIHARA Dai
The present invention addresses the problem of providing a SARS-CoV-2 detection kit and a SARS-CoV-2 detection method that enable the detection of SARS-CoV-2 in a simple manner and with higher sensitivity. The present invention provides a SARS-CoV-2 detection kit for specifically detecting a nucleocapsid protein (NP) contained in a biological sample, the SARS-CoV-2 detection kit comprising at least one antibody that specifically reacts with a SARS-CoV-2 nucleocapsid protein (NP), wherein the antibody includes at least one antibody of which the subclass is IgG2b, and the kit includes a first container that receives a silver-containing compound, and a second container that receives a reducing agent that can reduce silver ions.
2.WO/2022/105772BISPECIFIC ANTIBODY HAVING NEUTRALIZING ACTIVITY AGAINST CORONAVIRUS, AND USE THEREOF
WO - 27.05.2022
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
 Appl.No PCT/CN2021/131080 Applicant SANYOU BIOPHARMACEUTICALS CO., LTD. Inventor LANG, Guojun
Provided are a bispecific antibody having a neutralizing activity against a coronavirus, and a use thereof. A neutralizing antibody which is against a coronavirus S protein and blocks the binding of the coronavirus S proteins to an ACE 2 receptor is provided to prevent and treat coronaviruses. Specifically provided is an antibody or polypeptide complex specifically binding to a coronavirus S protein, comprising: (a) a first epitope binding moiety comprising a heavy chain variable region VH and a light chain variable region VL, wherein the VH and VL form an antigen binding domain specifically binding to a first epitope of an S protein; and (b) a second epitope binding moiety comprising a single-domain antibody or a VHH fragment thereof specifically binding to a second epitope of the S protein, wherein the first and second epitope binding portions are fused to each other and are not identical to each other. Also provided is a polynucleotide for encoding an antibody or a polypeptide complex and a host cell comprising same, and a method for preparing an antibody or a polypeptide complex. The antibody or polypeptide complex can be used for preventing, treating, diagnosing, and/or detecting coronaviruses.
3.WO/2022/109071PARTICLE-BASED DETECTION OF ANALYTES
WO - 27.05.2022
Int.Class G01N 33/48
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
 Appl.No PCT/US2021/059791 Applicant XIBUS SYSTEMS, INC. Inventor SWAGER, Timothy Manning
Particle-based detection of analytes including, for example, systems, kits, and methods for growth, isolation, and/or monitoring of analytes are generally disclosed. In some embodiments, the systems and methods described herein are generally directed to the capture and/or concentrating of a target species (e.g., analyte) to be detected and/or monitored. In some embodiments, the materials, systems, and methods described herein may be used to create luminescent signals in response to the presence of selected analytes such as bacteria, viruses, and parasites. In some cases, the target analyte is a pathogenic bacteria, a pathogenic virus, a pathogenic parasite, or toxin.
4.WO/2022/108897USE OF MICROVIRIN IN THE IDENTIFICATION OF MYCOBACTERIUM TUBERCULOSIS MANNOSE-CAPPED LIPOARABINOMANNAN
WO - 27.05.2022
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 Appl.No PCT/US2021/059448 Applicant VANDERBILT UNIVERSITY Inventor VAN DER HORST, Megan
The present disclosure is directed to the use of microvirin-N in the detection of Mycobacterium tuberculosis infections.
5.WO/2022/105896A TEST STRIP FOR RAPID DETECTION OF CONTAMINATION BY A VARIETY OF VIRUSES OR PATHOGENS
WO - 27.05.2022
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 Appl.No PCT/CN2021/131924 Applicant HANGKE ZHONGTOU BIOTECHNOLOGY (BEIJING) CO., LTD. Inventor LI, Hong
A test strip for rapid detection of contamination by a variety of viruses or pathogens, which is composed of a sampling pad (110), a conjugate pad (120), a reaction and coloration membrane (130), an adsorbent pad (100) and a supporting plate, the sampling pad (110) and the liquid-absorbing pad (100) are respectively arranged on opposite sides of the supporting plate. The conjugate pad (120) includes biotinylated antiviral antibody and anti-rabbit IgG antibody. The reaction and coloration membrane (130) is made of a nitrocellulose membrane, on the surface of which a positive control marker including non-specific rabbit IgG as well as a variety of complex specific antiviral antibody markers are provided. By combining multiple complex antibodies and multiple specific virus antibody markers, it is possible to detect the pollution of multiple viruses or pathogens simultaneously, thereby improving efficiency and reducing cost.
6.WO/2022/104918BISPECIFIC ANTIBODY HAVING NEUTRALIZING ACTIVITY AGAINST CORONAVIRUS, AND USE THEREOF
WO - 27.05.2022
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
 Appl.No PCT/CN2020/133194 Applicant SANYOU BIOPHARMACEUTICALS CO., LTD. Inventor LANG, Guojun
A bispecific antibody having neutralizing activity against coronavirus and the use thereof. Provided is a neutralizing antibody against a coronavirus S protein and for blocking same from binding to an ACE2 receptor to prevent and treat coronavirus. Specifically, the present invention relates to an antibody or a polypeptide complex that specifically binds to the coronavirus S protein, which antibody or polypeptide complex comprises: (a) a first epitope binding moiety, which comprises a heavy chain variable region VH and a light chain variable region VL, wherein VH and VL form an antigen binding domain of a first epitope that specifically binds to the S protein; and (b) a second epitope binding moiety, which comprises a single-domain antibody of a second epitope that specifically binds to the S protein, or a VHH fragment thereof, wherein the first and second epitope binding moieties are fused to each other and are different from each other. The present invention also relates to a polynucleotide encoding the antibody or polypeptide complex, a host cell comprising same, and a method for preparing the antibody or polypeptide complex. The antibody or polypeptide complex can be used to prevent, treat, diagnose and/or detect coronavirus.
7.WO/2022/107089DEVELOPING LATERAL FLOW IMMUNOCHROMATOGRAPHY (LFIA) PEPTIDE-BASED TEST STRIPS FOR RAPID DETECTION OF ANTIGENS AND ANTIBODIES AGAINST SPECIFIC ANTIGENS
WO - 27.05.2022
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
 Appl.No PCT/IB2021/060795 Applicant KING ADBULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY Inventor A.E. HAUSER, Charlotte
The present disclosure relates a method of fabricating a literal flow immunoassay (LFIA) for the diagnosis of diseases, including COVID-19. The present disclosure further relates to a fusion-epitopes peptide that can be used in the LFIA test to improve sensitivity, specificity and accuracy of the test.
8.WO/2022/109155POLYNUCLEOTIDE NANOSTRUCTURES FOR DETECTING VIRAL INFECTIONS AND OTHER DISEASES
WO - 27.05.2022
Int.Class C12Q 1/6816
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6813Hybridisation assays
6816characterised by the detection means
 Appl.No PCT/US2021/059919 Applicant ATOM BIOWORKS, INC. Inventor WANG, Xing
The present disclosure relates to polynucleotide nanostructures and techniques that use polynucleotide nanostructures as bimolecular recognition entities for detecting viral infections, e.g. Covid-19, and other diseases. For example, an artificial biopolymer complex can include a network of polynucleotides including structural units connected to one another via a series of arms and junctions, e.g. in the form of a DNA Star. Intersections of three or more arms form the junctions at a predetermined distance from one another. The artificial biopolymer complex further includes binders, e.g. aptamers, attached to the network of polynucleotides that can bind to antigens of a target analyte. The binders are attached at loci on one or more of the arms forming the junctions. The loci are separated by predetermined inter¬ binder distances such that the binders are positioned on the network of polynucleotides in a predetermined two-dimensional or three- dimensional spatial pattern that matches a two-dimensional or three- dimensional spatial pattern of the antigens on the target analyte. The nucleic acid oligonucleotides, e.g. the aptamers, from which the nanostructure is formed may be labelled with fluorophores and/or quenchers to detect the binding to a target.
9.WO/2022/108013CORONAVIRUS INFECTIOUS DISEASE COVID-19 THERAPEUTIC PROTEINS CTP ALPHA, CTP BETA, CTP GAMMA, CTP DELTA, AND USES THEREOF
WO - 27.05.2022
Int.Class C07K 14/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
 Appl.No PCT/KR2021/005678 Applicant DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY Inventor CHANG, Iksoo
The present invention relates to coronavirus infectious disease COVID-19 therapeutic proteins CTP alpha, CTP beta, CTP gamma, CTP delta, and uses thereof. Compared to a known peptide (P6) which mimics the binding site of a receptor binding domain (RBD) of SARS-CoV and angiotensin-converting enzyme 2 (ACE2), the therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta according to the present invention comprise a novel part obtained by adding a novel sequence of amino acids, wherein the interaction of atoms constituting the amino acids has been fundamentally designed in order to strengthen the binding of SARS-CoV2 to a novel epitope of RBD. The present invention provides therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta having a novel design and capable of binding more strongly than known peptides due to being creative designs of the extended therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta, wherein the therapeutic proteins can additionally interact with charged amino acids of D420 and K458 on the rear side of the conventional binding interface between RBD and hACE2 or additionally interact with charged amino acids such as R454, K458, D467, and E471. The therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta according to the present invention have the potential of being highly applicable as COVID-19 therapeutic agents.
10.WO/2022/106423APPARATUS
WO - 27.05.2022
Int.Class B01L 3/00
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
3Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
 Appl.No PCT/EP2021/081870 Applicant TTP PLC Inventor CROSSLEY, Peter
The invention relates to a pathogen testing system that can analyses multiple samples at once in order to provide guidance on the presence of an infection in a given environment. This reduces the number of individual tests that are needed and provides enhanced confidence as to the levels of pathogen in a given environment.
# -